Unique ID issued by UMIN | UMIN000032875 |
---|---|
Receipt number | R000037487 |
Scientific Title | Feasibility study of radiotherapy using CyberKnife for metastatic lung tumors from adenoid cystic carcinoma |
Date of disclosure of the study information | 2018/07/01 |
Last modified on | 2021/06/07 09:51:31 |
Feasibility study of radiotherapy using CyberKnife for metastatic lung tumors from adenoid cystic carcinoma
Feasibility study of radiotherapy using CyberKnife for metastatic lung tumors from adenoid cystic carcinoma
Feasibility study of radiotherapy using CyberKnife for metastatic lung tumors from adenoid cystic carcinoma
Feasibility study of radiotherapy using CyberKnife for metastatic lung tumors from adenoid cystic carcinoma
Japan |
metastatic lung tumors from adenoid cystic carcinoma
Radiology |
Malignancy
NO
To evaluate the safety of radiotherapy using CyberKnife for metastatic lung tumors from adenoid cystic carcinoma
Safety
Toxicity
Observational
12 | years-old | <= |
95 | years-old | >= |
Male and Female
1) diagnosed as metastatic lung tumors from adenoid cystic carcinoma in clinical course
2) measurable tumors
3) a performance status of 0-2
The presence of other primary cancers
5
1st name | Tsuneo |
Middle name | |
Last name | Shimizu |
Kanto Neurosurgical Hospital
Cyber Center
360-0804
1120, Dai, Kumagaya, Saitama 360-0804 JAPAN
048-521-3133
kantou@ps.ksky.ne.jp
1st name | Hiro |
Middle name | |
Last name | Sato |
Gunma University Graduate School of Medicine
Department of Radiation Oncology
371-8511
3-39-22 Showa-machi, Maebashi, Gunma 371-8511 JAPAN
027-220-8383
h-sato0808@hotmail.co.jp
Kanto Neurosurgical Hospital
Kanto Neurosurgical Hospital
Other
Kanto Neurosurgical Hospital
1120, Dai, Kumagaya, Saitama 360-0804 JAPAN
048-521-3133
kantou@ps.ksky.ne.jp
NO
2018 | Year | 07 | Month | 01 | Day |
https://pubmed.ncbi.nlm.nih.gov/33838695/
Partially published
https://pubmed.ncbi.nlm.nih.gov/33838695/
1
The patient underwent SBRT at 60 Gy in 10 sequential fractions for each tumor. The biologically effective dose based on an alpha/beta ratio of 2 Gy was 240 Gy per tumor. The percentage of the total lung volume irradiated with >20 Gy was 4.9%, 3.2%, and 2.6% for each tumor.
2021 | Year | 06 | Month | 07 | Day |
A 76-year-old Japanese man with ACC who was treated with carbon ion radiotherapy for a primary oropharynx tumor presented with three metastatic lesions in the lung.
The total dose was 64 Gy (relative biological effectiveness) delivered in 16 fractions. After 30 months, there was no recurrence of the primary lesion; however, the metastatic lung tumors had increased in size.
The patient developed acute radiation pneumonitis during the initial therapy, which resolved at 6 months after the CyberKnife treatment. At 21 months after the first CyberKnife treatment, three tumors showed no signs of recurrence. No late toxicity was observed.
The patient underwent SBRT at 60 Gy in 10 sequential fractions for each tumor. The biologically effective dose based on an alpha/beta ratio of 2 Gy was 240 Gy per tumor. The percentage of the total lung volume irradiated with >20 Gy was 4.9%, 3.2%, and 2.6% for each tumor.
Main results already published
2018 | Year | 06 | Month | 05 | Day |
2018 | Year | 06 | Month | 05 | Day |
2018 | Year | 06 | Month | 07 | Day |
2019 | Year | 12 | Month | 25 | Day |
2019 | Year | 12 | Month | 25 | Day |
1) diagnosed as metastatic lung tumors from adenoid cystic carcinoma in clinical course
2) measurable tumors
3) a performance status of 0-2
2018 | Year | 06 | Month | 05 | Day |
2021 | Year | 06 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037487